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Opinion statement
Treatment of dengue remains supportive in the absence of targeted antiviral therapy or
approved vaccines. Responsive fluid management is key to preventing progression to
shock or other severe manifestations. The dynamic natural history of dengue infection and
its influence on hemodynamic homeostasis needs to be carefully considered in the
planning of individualized therapy. Though largely self-limiting, the sheer burden of
dengue disease on the global population will result in atypical manifestations especially
in children, older adults, and comorbid patients. Management of these has not yet been
systematized. The failure of recent randomized controlled trials to show utility for antiviral
and immunomodulatory agents in dengue is disappointing. Vaccine candidates hold
promise, but growing outbreaks require more robust, evidence-based management guide-
lines to inform clinicians, especially in novel epidemic situations.
Introduction
Dengue is caused by a flavivirus comprising four
established serotypes (DENV1–4), with a fifth serotype
recently proposed [1]. Dengue has the greatest reach of
all arthropod-borne viral (arboviral) infections, with an
estimated 390 million infections a year [2]. Dengue
infection manifests with a variety of clinical syndromes,
from asymptomatic infection, to undifferentiated acute
febrile illness, to dengue hemorrhagic fever and severe
dengue, including dengue shock syndrome [3•]. Histor-
ically, dengue has been one of a number of mosquito-
borne acute febrile illnesses, and differentiation from
other flaviviruses such as yellow fever, alphaviruses such
as chikungunya, or parasitic infections such as malaria
has not always been possible when attributing etiologic
agents to historic outbreaks from the late 18th century
until the isolation of dengue virus in 1943 [4, 5].
One of the earliest accounts of what was then known
as breakbone fever or Dandy fever was by Benjamin
Rush, describing the outbreak in Philadelphia in 1780
[6]. He already recognized that the vast majority of
patients recover without major complications after suf-
fering for a few days of fevers and aches. He
recommended bed rest (rather than exercise), and treat-
ed patients with emetics and laxatives following the
practice of the day, along with opiates. He recognized
the occasional complication from bleeding and warned
against blood letting, otherwise a popular recourse. Sim-
ilar treatment for this largely non-fatal fever continued
to be recommended by physicians in the outbreaks of
the early 19th century, for example in India [7], Zanzibar
(Tanzania) [8], and South Carolina [9]. As one of many
tropical fevers, generic folk remedies recorded historically
and currently in vogue included porcupine bezoars [10–
12] and papaya leaf extract. Several publications examin-
ing the latter in the context of dengue infection have
given equivocal results [13–16]. Into the early 20th cen-
tury, treatment has remained supportive, primarily com-
prising analgesics and antipyretics for symptomatic relief,
with the management of complications as they arise,
such as bleeding, dehydration, shock, or organ failure.
The impact of dengue precipitously increased after
World War II where a host of epidemiologic and ecolog-
ic factors affecting the spread of Aedes aegypti, urbani-
zation trends, and increased global travel led to large
pediatric epidemics with high mortality in southeast
Asia [17] and later in the Americas [5]. The clinical
experience derived from these epidemics allowed
physicians to develop clinical protocols to reduce mor-
tality, which were promulgated by the World Health
Organization (WHO) [18]. The key intervention was
understood to be intensive intravenous fluid adminis-
tration to counteract the fluid leak from capillaries in the
critical defervescent phase, when children in particular
are prone to develop shock and organ failure. Develop-
ment of the concept of dengue hemorrhagic fever as a
syndromic precursor to shock and death led to an em-
phasis on identifying candidates for judicious rehydra-
tion by frequent monitoring of blood pressure,
haematocrit, and signs of shock such as capillary refill
and other signs of peripheral circulatory collapse. Imple-
mentation of standardized treatment guidelines led to a
marked reduction in case fatality from over 13 % to less
than 0.1 % in Thailand [19]. Increasing adherence to
guidelines (primarily encouraging oral rather than intra-
venous fluid therapy where appropriate) has been
shown to lead to gains in resource use in dengue case
management without adversely affecting morbidity or
mortality in Nicaragua [20]. The importance of optimiz-
ing guidelines locally has also been shown in Singapore,
where significant cost savings were associated with re-
ductions in unnecessary hospitalization after admission
criteria were modified and more strictly enforced [21].
Treatment guidelines
Dengue management algorithms have been developed by the WHO South East
Asia Regional Organization (SEARO) and the WHO Pan American Health
Organization, which have been further adapted in national guidelines. The
premise is distinction of dengue disease from other tropical fevers, for which
clinical criteria alone are not sufficiently discriminatory, especially in older
adults [22–24]. Diagnostic testing is strongly recommended, summarized in
Table 1. In brief, in endemic areas or in likely immune populations with past
exposure to dengue or other related flaviviruses, reverse transcription-
polymerase chain reaction (RT-PCR) and non-structural protein 1 (NS1) detec-
tion aremost useful because of their specificity, particularly in early presentation.
In late presentation, clinical manifestations may have to guide management
with a battery of repeated tests requiring evidence synthesis by experienced
physicians to determine etiology. In travelers or other non-immune populations,
in addition to RT-PCR andNS1 in the early or febrile phase, immunoglobulinM
and immunoglobulin Gmay bemore useful, but with caveats about accuracy. In
the context of an acute undifferentiated tropical fever otherwise negative for
common etiologic agents such as Plasmodium or Salmonella, the combination of
leukopenia, severe thrombocytopenia (G50 000/mm3), rapid changes in he-
matocrit (920 % change from baseline or initial value), and elevated
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transaminases with an asparatate transaminase:alanine transaminase ratio of 91
make dengue the prime candidate. Mild cases that do not reach these values are
likely self-limiting or may not benefit from currently available treatment.
There is significant variation between the revised WHO 1997 guidelines [47],
regional guidelines [48•, 49], and national guidelines [50]. Subsequently, rec-
ognizing the limitations in the sensitivity of depending solely on a strict adher-
ence to dengue hemorrhagic fever criteria (fever, thrombocytopenia, capillary
leak, and hemorrhagic tendency) to determine treatment prioritization [51],
WHO proposed new dengue severity classifications and adjusted management
algorithms in 2009 [52] and expanded treatment guidelines in 2012 [53••].
While the key principles of timely and judicious fluid repletion are maintained,
different criteria have been proposed for triage, hospital admission, and intensive
care unit admission, as well as initiation, rates, and cessation of intravenous fluid
administration. Criticism of this new guideline centers around two aspects. First,
progression to severe dengue is not considered as a single pathophysiologic entity
but as a diverse set of manifestations, complicating the streamlining of manage-
ment, especially by inexperienced staff, and hampering focused pathogenesis
research [54]. Second, the broader criteria for clinical diagnosis of dengue and
particularly dengue requiring hospitalization is regarded as potentially prob-
lematic, taking into account the lack of rapid definitive dengue laboratory
diagnosis and lack of inpatient beds especially in outbreak situations [55–58].
Fluid management
The primary modality for therapeutic intervention in dengue is fluid manage-
ment. The fundamental principle building on experience in Thailand from the
post-war period until now and articulated most clearly in the recent WHO
SEARO guidelines [48•] is of dengue as a triphasic syndrome. In the initial
febrile phase lasting 3–7 days, serum viremia is present, and increasing capillary
permeability leads to a rise in hematocrit. This may be exacerbated by dehy-
dration due to anorexia, nausea, vomiting, diarrhea, andmalaise. Together with
the development of a serologic response, and associated with defervescence, the
critical phase is one where intervention can make the most difference. This is
when immunopathologic responses are maximal, reflected in a platelet nadir
and rapid rise in hematocrit as fluid shifts out of the intravascular space into the
interstitium and third spaces. There is the greatest risk of organ dysfunction
exacerbated by edema and microvascular changes during the critical phase,
which lasts 1–2 days. The possibility of iatrogenic fluid overload through
cumulative fluid administration is also greatest here. Subsequently, during the
convalescent phase, blood dyscrasias normalize, inflammatory markers settle,
and fluid shifts back into the vasculature. There is a risk of hemodynamic stress
if the patient was in fluid overload and the shift of interstitial fluid overwhelms
the capacity of the cardiovascular system at this point.
As this dynamic process unfolds, clinical fluid interventions are overlaid on
this shifting landscape, making identification of the stage the patient is at the
key to good management. Unfortunately, no simple algorithm is able to
categorize patient response, given the wide range of variation of ages and fitness
represented. Those at higher risk of being unable to cope with these fluid shifts
as measured by changes in microvascular permeability (such as children, or
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those genetically predisposed) may be at higher risk of shock [65]. Clinical
judgment taking into number of days since fever onset, body temperature,
blood pressure, signs of peripheral circulatory status, and signs of fluid overload
including radiographic and ultrasonographic studies is required.
Importantly, goal-directed therapy in dengue shock is different from that in
septic shock as the physiologic and homeostatic context of the cardiovascular
system is distinct in these two syndromes. Even in the fluid management of
infection-associated shock, existing guidelines have been called into question
by the FEAST trial that showed standard fluid boluses given in hypotension led
to increased mortality in such pediatric cases [66]. In addition to goal-directed
therapy using catheter-based blood pressure measurement and targets, a more
sophisticated approach taking into account measures of tissue perfusion, fluid
balance, and capillary leak may be required [67]. These may include such
emerging non-invasive technologies such as photoplethysmographywhich uses
changes in pulse oximetry waveforms to indicate changes in cardiovascular
status [68], and is being studied in the context of dengue [69].
Dengue patients can be differentiated into three categories for the purposes of
fluidmanagement:mild dehydration; significant dehydration at risk of shock or in
compensated shock; and decompensated shock due to fluid leakage. Patients may
stay in the first category throughout their illness, or move into the second category
just before and during the critical phase, or progress further into the third category
during the critical phase. The time-dependent progression is important as, for
example, aggressive fluid therapy for presumed compensated dengue shock if
given early in the course of illness and for a prolonged period of timemay lead to
fluid overload Table 2 summarizes the key management decision points for
clinicians, with selected issues discussed further below.
Treatment of mild dehydration is the mainstay of hospitalized dengue. Oral
rehydration using isotonic electrolyte solutions or similar fluids such as coconut
water or rice water are recommended in many guidelines. These carry less risk of
iatrogenic fluid overload than intravenous administration and have been asso-
ciated with decreased resource use while maintaining safe outcomes [20]. Anti-
emetics may be useful to control vomiting. Mild hypokalemia is often encoun-
tered, likely associated with vomiting and diarrhea, but is seldom of sufficient
magnitude to cause clinical significance and resolves in early convalescence.
Those in the second category may be identified by rapidly rising hematocrit,
rapid drop in serum protein or albumin levels, or clinical fluid accumulation
such as pulmonary edema and ascites. These are components of the definition
of dengue hemorrhagic fever, which requires in addition signs of hemorrhage
and thrombocytopenia. Whether the latter are essential to the assignment of at-
risk status needing additional fluid administration has been controversial, with
the latest WHO SEARO guidelines emphasizing capillary leak criteria over
hemorrhagic criteria in determining fluid management [48•]. Determining
numerical thresholds for these criteria is challenging given individual physio-
logic variation. Guidelines currently refer to relative changes in hematocrit over
10 % as a warning sign and changes over 20 % as a clear indication for more
aggressive fluid therapy. Onemodel for guiding fluid administration follows an
inverted ‘V’ pattern over 48 h, rising from 40mL/h to 200mL/h and falling back
to 40 mL/h in adults [48•]. Judicious fluid management requires frequent
monitoring and sensitivity to clinical status. Isotonic crystalloid is universally
recommended in uncomplicated cases except in infants where half-molar
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sodium chloride may be used [52]. It should be reiterated that the rates of
intravenous fluid administration detailed above are envisioned to be used over
a 24- to 48-h period, and subject to clinical monitoring as significant morbidity
and mortality can result from fluid overload [70]. The WHO 2009 guidelines
also suggest that warning signs are indications for an increased intravenous
fluid administration rate over maintenance. There has been vigorous discussion
regarding this as the list of warning signs are clinically varied and do not
describe a single pathophysiologic syndrome [54], so it may be more appro-
priate to individualize fluid administration rates rather than group them to-
gether under one protocol.
By good fluid management at the transition to the critical phase, the aim is
primary prevention of progression to shock. If dengue progresses into shock
because of fluid leakage, management should be in an intensive care setting,
with the ultimate goal to maintain tissue perfusion. Intensive care protocols
such as surviving sepsis bundles will often be applied, but should be tempered
by recognition of the different context of fluid shifts in dengue compared with
septic shock. Protocols are given in WHO guidelines, including evidence from
randomized controlled trials that initial treatment can begin with crystalloid
infusions, with hyper-oncotic colloids as a second-line agent where response is
not optimal [71, 72]. The ideal is to titrate intravenous fluids along the natural
progression of dengue fluid leak, which increases then decreases sharply during
the 24- to 48-h critical phase, to blunt the impact on tissue perfusion and
hemodynamic homeostasis. The WHO SEARO 2011 guidelines highlight that
obese patients should not be given fluids according to actual body weight but
according to ideal body weight to avoid fluid overload.
Antiviral and other targeted therapy
There are as yet no specific antiviral therapies for dengue. Active research is
ongoing using in vitro and animal models [73], but few drugs have entered
clinical trials. Chloroquine has been shown to be ineffective in reducing viremia
[74] and disease duration but may offer limited symptomatic relief [75]. Dengue
antiviral research has benefited from the recent intensive effort to discover drugs
for the treatment of hepatitis C virus (HCV), a fellow flavivirus. A number of HCV
drugs that have pre-clinical efficacy against dengue virus have been repurposed
and moved on to phase II clinical trials for dengue. Balapiravir was shown to be
safe in adults with dengue, but did not lead to changes in the kinetics of viremia
or cytokine profiles [76]. Celgosivir, also a repurposed HCV candidate, has
similarly shown a lack of success in reducing viral load or fever in patients with
dengue [77]. Other candidates are in the drug discovery pipeline, which has been
growing with increased global emphasis on neglected tropical diseases [78].
Finally, there is a potential for using dengue-specific antibodies therapeutically by
neutralizing dengue virus [79]. The key hurdle to this is ensuring that antibody-
dependent enhancement of DENV infection does not take place.
Immunomodulatory agents
A major component of dengue disease is a result of immunopathology, for
which the metaphor of a cytokine storm has been used. In the process of
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attempting to eliminate dengue virus, changes in physiology occur which, if
transient, result in a good outcome after a period of acute morbidity, but in
cases where the host physiology is not robust enough to weather the change
(e.g., in children or older adults), irreversible damage may result. Though
our understanding of the precise nature of the immune response against
dengue is still in development, attempts have been made to trial immuno-
modulatory agents. Intravenous immunoglobulin has been shown to lack
efficacy [80, 81]. Recent guidelines have emphasized the lack of evidence for
using corticosteroids [82]. A small randomized controlled trial was con-
ducted in Pakistan that showed a limited but statistically significant differ-
ence in platelet recovery between treatment and placebo groups using
interleukin-11; however, no other clinically significant endpoints were used
[83]. Finally, statins exhibit pleiotropic effects on the inflammatory response
in humans [84, 85] and antiviral effects in mouse models of dengue [86]. A
randomized controlled trial is in progress in Vietnam to assess the effect of
lovastatin in dengue [87].
Vaccine development
A dengue vaccine has been held out as the hope for disease control and
eradication since 1929 when the first candidates were evaluated [88, 89]. To
date, the Gates Foundation’s strategy for dengue is enhanced vaccine research
rather than drug discovery. There has been a range of vaccine candidates
proposed, using live attenuated virus, chimeric virus, inactivated virus, subunit
vaccines, and DNA vaccines [90]. In addition to the usual concerns of safety and
immunogenicity, dengue vaccines have been stymied by the prospect of
antibody-dependent enhancement, a feature that risks worsening the effect of
dengue infection through immunologic memory [91]. This results from the
presence of four potentially cross-reactive serotypes, as well as the potential for
cross-reactivity with related flaviviruses. All candidates have to be extensively
investigated to ensure this theoretical risk is eliminated. There is currently only
one candidate in phase III efficacy trials; however, the initial report from a phase
IIb pediatric cohort in Thailand indicated poor vaccine efficacy against DENV-2
[92••]. The results of the full trial in Asia and Latin America are awaited eagerly.
Systems-based management
Systemic manifestations: pyrexia
The role of antipyresis in infectious fevers remains inconclusive with the aim
being primarily symptomatic relief and the effect on clinical measures of
microbiologic clearance, morbidity (e.g., febrile seizures), and mortality not
well established [93, 94]. In dengue, the febrile phase generally lasts 3–7 days
with an upper limit of 10 days in unusual cases. A biphasic (or saddleback)
pattern has been reported in some cases with a transient defervescence around
day 5 and subsequent progression to the critical phase associated with risk of
shock and immunolopathologic manifestations. Limited research has been
conducted on pharmacologic (paracetamol/acetaminophen) [95] and physical
(sponging) methods [96] of antipyresis but both remain recommended in the
WHO guidelines for dengue [52]. The utility for analgesia may contribute to the
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near-universal use of paracetamol in dengue. However, the inherent potential
for liver toxicity as an adverse effect with paracetamol may be magnified by the
tendency of dengue to cause liver inflammation as measured by elevated
aminotransferase levels [97–99]. Non-steroidal anti-inflammatory drugs are
contraindicated because of the danger of exacerbation of bleeding in the context
of depressed platelet levels during acute dengue. For patients receiving long-
term antiplatelet therapy with aspirin, clopidogrel, or similar agents, physicians
may consider temporarily withholding these drugs until the thrombocytopenia
during acute dengue improves, as the risk of thromboembolism during this
period is reduced and risk of hemorrhage increased. Finally, corticosteroids
have been shown in randomized controlled trials to have no significant impact
on outcomes in severe dengue [82, 100–102]. Though not recommended in
guidelines, there remain anecdotal reports of their use in symptomatic relief,
though the complex immunopathology of dengue should give physicians
reason for careful consideration before use. One important factor in the use of
antipyretics for dengue is the critical dependence on the recognition of pro-
gression from the febrile phase to the critical (defervescent) phase with the
concomitant shifts in fluids that take place during this progression. The ame-
lioration of pyrexia can confuse determination of what phase the patient is in,
and subsequently affect decisions on fluid management that depend on the
shifting intravascular versus third-space fluid volume of the patient.
Musculoskeletal manifestations
Aches and pains are of major clinical significance during dengue, being key
symptoms that aid in clinical diagnosis and often are the primary concern of the
patient. Bed rest and paracetamol remain the mainstays of management. Less
commonly, opiates or even corticosteroids have been used [103]. Rhabdomy-
olysis, reflected in raised serum creatinine kinase is a recognized complication
[104], which in rare cases can lead to acute kidney injury, recently confirmed in
one case report with a renal biopsy [105]. In most mild cases, adequate
hydration that follows the standard of care for dengue will help recovery.
Progression to renal dysfunction though may necessitate hemodialysis. There
may also be transient muscle dysfunction associated withmuscle weakness and
hyporeflexia that does not require treatment and is generally self-limiting [106].
Dermatologic manifestations
Cutaneous changes in dengue can be polymorphic [107, 108]. The classical
dengue rash occurs in two phases: in the early febrile period, generalized
flushing occurs, sometimes manifesting as a morbiliform erythematous macu-
lar rash, followed in the late febrile and defervescent period by the typical
maculopapular rash with “islands of sparing” alongside petechiae and ecchy-
moses associated with severe thrombocytopenia. In a small number of cases,
recovery may be delayed by days to weeks after defervescence, with some
residual macular erythema consistent with a delayed-type, T-cell-associated
cutaneous reaction. Apart from patient anxiety from the cosmetic effect of the
rash that can be alarming in its intensity and spread, the main treatable sequela
is pruritis, which occurs in a large proportion of cases. Antihistamines can be
used, where the adverse effect of drowsiness may fortuitously aid in supporting
bed rest.
Dengue: Current Standard of Care to State-of-the-Art Treatment Gan 217
Opthalmic manifestations
Generally, visual disturbances are rare in dengue, but a number of case series
have been reported from epidemics in Singapore [109–112] and India [113,
114]. Symptoms include blurring of vision, subconjunctival hemorrhage, eye
flashes, floaters, and retro-orbital pain. Pathologic causes identified include
maculopathy, exudates, retinal hemorrhage, retinal detachment, vasculitis,
foveitis, choroiditis, and uveitis. These largely occur during the critical
(defervescent) phase of dengue and resolve in the convalescent phase, though
persistence has been described in a few individuals. Serotype association has
been proposed [115] as well as a relationship to autoimmune disease [116].
Full recovery usually occurs in the absence of specific treatment, though
systemic and topical corticosteroids have been given with good results in
a few cases.
Neurological manifestations
A recent review of neurologic complications of dengue virus infection used the
following categories: encephalopathy, encephalitis, and immune-mediated
syndromes in addition to muscular and ophthalmic involvement already cov-
ered [117•]. Lack of biopsy findings often precludes definitive diagnosis, as
does difficulty in proving dengue virus involvement, especially in regions
endemic for cross-reactive flaviviruses where interpretation of serologic testing
is not straightforward. Further, when large outbreaks occur that affect significant
proportions of residents, Occam’s razor may not apply and acute confusional
states may have multiple infective or other etiologies. Encephalopathy may be
multifactorial, exacerbated by acute liver failure, metabolic derangements,
shock, or intracranial hemorrhage. Dengue-associated encephalitis often does
not display classical radiographic characteristics of viral encephalitides. These
should be treated according to evidence-based guidelines to optimize out-
comes. Otherwise, treatment for central nervous system complications of den-
gue remains supportive. Some anecdotal success has been reported using cor-
ticosteroids or intravenous immunoglobulin for immune-mediated complica-
tions [118, 119] but no randomized controlled trials have taken place.
Hematologic manifestations
Neutropenia, lymphocytopenia, and thrombocytopenia are all cardinal signs of
dengue virus infections that usually resolve within 1–2 weeks. Despite severe
neutropenia with an absolute neutrophil count of less than 0.5×109/L occur-
ring in 12 % of one dengue cohort, it was not associated with poorer outcomes
or an increase in secondary infections, and usually resolved within 1 day, thus
there may not be a need for routine prophylactic antibiotics [120]. A single case
report of the use of filgrastim as rescue therapy for persistent neutropenia in a
case with multiple complications and delayed defervescence has been pub-
lished [121]. The use of granulocyte-colony-stimulating factor has also been
described in one Thai pediatric case [122]. Lymphopenia is often the first to
resolve, with a rapid increase of reactive lymphocytes being the earliest sign
occurring during the defervescent phase. No specific therapy has been described
for this.
Thrombocytopenia is of the most concern because of the increased risk of
hemorrhage. Minor mucosal bleeding is relatively common, particularly
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transient gingival bleeding or epistaxis, which may be treated with gentle
pressure. Tranexamic acid, an anti-fibrinolytic agent, has been suggested in such
cases, though it has not yet been formally evaluated in dengue [123, 124].
Excessive vaginal bleeding occurred in 27 % of female adolescents in one Thai
study [125] who were treated with premarin, primulute N, or oral contraceptive
pills. Oral northethisterone has also been recommended in dengue-associated
hypermenorrhea [126]. Gynecologic practice for acute dysfunctional uterine
bleeding in general has shifted away from oral hormonal therapy to tranexamic
acid and mefanamic acid [127–129]. While the use of the latter in dengue is
problematic, tranexamic acid may prove to be useful and awaits further re-
search. Gastrointestinal bleeding in dengue always has the potential to be
catastrophic because of its occult nature. In mild cases where no major hem-
orrhage is suspected, the use of proton pump inhibitors may have a favorable
risk-to-benefit ratio. There is no evidence that platelet transfusion as primary
prophylaxis in the absence of bleeding independently reduces the risk of
bleeding or other severe outcomes [130–132].
Where bleeding is persistent, the administration of platelets may be consid-
ered, despite the transience of the effect on platelet levels. However, if blood loss
is significant, administration of packed red cells or fresh whole blood is more
urgent. Evidence for bleeding may be complicated to assess where bleeding is
occult. Watching hemoglobin levels in isolationmay give an incomplete picture
because of the dynamic fluid shifts in dengue especially during the critical
phase. Close watch of the hematocrit, clinical fluid accumulation, fluid balance,
and hemodynamic status will provide a more complete picture to determine if
the management of bleeding is necessary. Differentiating shock because of
hemoconcentration and hemorrhagic shock is critical as the management is
fundamentally different. Where bleeding remains uncontrolled, activated re-
combinant factor VII has been used with success [133, 134].
Thrombocytopenia itself has been used as a surrogate for impact on
dengue progression in various therapeutic trials without any agents identi-
fied as successful in significantly improving platelet recovery in acute infec-
tion, as in, for example, high-dose intravenous immunoglobulin [81]. In a
few cases, however, unusually persistent thrombocytopenia lasting far
beyond the usual convalescent recovery period has been successfully
treated with corticosteroids [135, 136].
Finally, there have been increasing reports of dengue-associated
hemophagocytic lymphohistiocytosis [137–142] worryingly often associat-
ed with death or identified post-mortem. Prompt diagnosis is difficult given
the need for biopsy and the complexity of the diagnostic criteria, and
treatment may include corticosteroids or intravenous immunoglobulin in
milder cases, to the use of cytotoxic and immunomodulatory agents under
several trial protocols [143].
Hepatic manifestations
While dengue-associated liver inflammation tends to be ubiquitous but tran-
sient, not requiring specific therapy [99], there are cases of acute liver failure
likely due to a combination of direct viral cytopathic effects, liver ischemia
through hemodynamic instability, and immunopathologic sequelae of infec-
tion [144]. Apart from supportive measures, a number of studies have
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promoted the use of N-acetylcysteine therapy in dengue-associated acute liver
failure [145–147]. There has also been one case report of successful use of the
molecular adsorbent recirculating system in dengue hemorrhagic fever [148].
Respiratory manifestations
Dengue shock can be associated with respiratory compromise as recognized in
the WHO 2009 guidelines [52] often associated with pleural effusion. In the
absence of dengue-specific guidelines, use of standard intensive care protocols
can be considered. One study recommended nasal continuous positive airway
pressure rather than oxygen mask treatment in dengue patients with respiratory
failure [149]. Pleural effusion can be the result of over-hydration leading to
extravasation and third-space accumulation of fluid. Judicious fluid adminis-
tration and frequent monitoring is critical to prevent this.
Cardiac manifestations
Three major syndromic cardiac manifestations of dengue infection are myocar-
dial impairment, arrythmias, and myocarditis [150•]. Apart from bradycardia,
which is common in dengue [151], subtle signs of dysfunction may only be
reflected in poorer than expected cardiovascular response to fluid infusion, which
is hard to quantify. However, in a Vietnamese case series of 79 pediatric dengue
patients uniformly subjected to echocardiography, over half showed signs of
myocardial impairment measured by preload-independent indices such as ve-
locities [152]. In an Indian case series of 67 children with severe dengue, 70 %
had abnormalities in the Tei index compared with 48 % by ejection fraction and
37%using the ratio of transmitral Doppler early filling velocity to tissue Doppler
early diastolic mitral annular velocity (E/E) while being mostly asymptomatic
[153]. As with other organ systems, pathogenesis is likely due to a combination
of direct viral cytopathic effects, metabolic derangement, cytokine-mediated
immunopathology, interstitial edema, andmicrovascular changes [150•]. Again,
while no dengue-specific protocols have been proposed, the use of standard
cardiology regimens has proven successful in case reports [154].
Conclusion
The impact of dengue has the potential for severe morbidity in young and
healthy individuals, especially in situations of massive outbreaks, as have been
happening, for example, in Lahore, Pakistan in 2011, with 500,000 notified
cases in a city of 5 million, and a dengue IgG seropositivity rate of 67.9 % the
following year in a city not previously endemic for dengue [155]. Physicians
unfamiliar with dengue may at short notice have to deal with critically ill
patients either in an outbreak or as a result of travel-related dengue infection
[156]. Management experience in severe dengue has largely occurred in the
context of pediatric cases. Because of demographic transitions, climatico-
ecologic change, and epidemiologic trends, adults are increasingly affected
and thus we may have to focus on ensuring guidelines remain relevant or
updated [157]. Increasingly, older adults are seen to be at risk from dengue-
related mortality [63, 158]. A broad range of virologic, immunologic, clin-
ical, and implementation science research will be required to combat this
emerging pandemic.
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